PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
This study is primarily designed to investigate whether treatment, once daily for up to three consecutive days, with PEP005 (ingenol mebutate) Gel, 0.05% will be safe and tolerable in patients with superficial Basal Cell Carcinoma (sBCC) lesions on the trunk and extremities.
Epistemonikos ID: db9f36eb76500431651d6684fab0e236e7be014c
First added on: May 06, 2024